title: The ethics of early evidence--preparing for a possible breakthrough in Alzheimer's disease.
authors.affiliation: Department of Bioethics, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
authors.forename: Justin
authors.initials: J
authors.lastname: Lowenthal
authors.forename: Sara Chandros
authors.initials: SC
authors.lastname: Hull
authors.forename: Steven D
authors.initials: SD
authors.lastname: Pearson
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy*; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use; D000077610:Bexarotene; D002986:Clinical Trials as Topic / Q000941:ethics; D004195:Disease Models, Animal; D017277:Drug Approval; D004992:Ethics, Medical; D006801:Humans; D051379:Mice; D056687:Off-Label Use / Q000941:ethics*; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D016588:Anticarcinogenic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene